 Drugs in Dev.
 Drugs in Dev.								 Gastroenterology
Gastroenterology
											 Discovery Platform
Discovery Platform
											
																			
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : nCycles
Therapeutic Area : Gastroenterology
Study Phase : Discovery Platform
Sponsor : Orbis Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Orbis and Vivtex Partner To Develop Oral nCycles Drugs
Details : The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs.
Product Name : nCycles
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : nCycles
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery Platform
Sponsor : Orbis Medicines
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery Platform
Sponsor : Siolta Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Nexilico and Siolta Partner On Microbiome Drug For Necrotizing Enterocolitis
Details : The collaboration combines Nexilico's AI-driven discovery platform with Siolta’s expertise in developing targeted biotherapeutics, setting the stage for the treatment approaches in infant health.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery Platform
Sponsor : Siolta Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $1,900.0 million
Deal Type : Collaboration
Details : GentiBio will apply its engineered regulatory T cell platform in a deal with BMS to develop new engineered Treg therapies to treat inflammatory bowel diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $1,900.0 million
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BX003
Therapeutic Area : Gastroenterology
Study Phase : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration BiomX will utilize its XMarker microbiome-based biomarker discovery platform with the goal of identifying biomarkers for a pathogenic bacterium thought to be associated with IBD.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : BX003
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration


 
															 Reset All
Reset All